Fedratinib Clinical Trials
Brain Disorder in Fedratinib Drug Trial Patients
Thomas J. Henry is currently investigating reports of Wernicke’s encephalopathy in clinical drug trial patients being treated with Sanofi’s experimental cancer drug fedratinib.
ABOUT THE FEDRATINIB CLINICAL TRIALS
Fedratinib, also referred to as SAR302503, was being tested as a possible treatment for a number of different blood cancers including myelofibrosis, polycythemia vera, and essential thrombocythemia.
The U.S. Food and Drug Administration ordered that clinical trials for the drug be placed on a partial hold following reports that trial participants had experienced an increased risk of developing Wernicke’s encephalopathy, a brain disorder that can result in eye problems, confusion, loss of coordination, and memory loss.
However, when follow-up investigations conducted by the FDA and independent researchers determined that the risks posed by fedratinib outweighed its benefits, Sanofi scrapped the drug completely.
FEDRATINIB CLINICAL TRIAL LOCATIONS
Clinical trials for fedratinib were held in cities nationwide including:
- Los Angeles
- San Francisco
- Kansas City
- Baton Rouge
- Ann Arbor
- New Jersey
- New York
- New York
- South Carolina
- San Antonio
- Salt Lake City